darzalex glow myeloma
sale pt
hike darzalex multipl myeloma mm peak sale
primarili base longer durat line use higher
penetr smolder underpin updat clinician
feedback remain confid darzalex alreadi chang mm treatment
paradigm backbon therapi reiter buy recent weak even
attract entri substanti undervalu darzalex royalti incom
mm sale updat phase castor pollux line mm
data suggest least month averag durat darzalex versu prior month
estim suggest prolong use line mm estim year
higher peak penetr smolder mm base encourag phase ii
data long-term declin use line therapi given emerg competit
darzalex chang mm treatment paradigm rapid adopt salvag
therapi darzalex set new standard follow use combo
line envisag use line mainten plu asymptomat
smolder diseas infus manag subcutan formul may
game-chang forecast ww peak sale mm
share npv plu risk-adjust sale indic md amyloidosi
conserv npv probabl first clinic data
drug solid tumour anticip around could substanti boost potenti
bcma fear overblown bcma target therapi perhap stole show
dec even assum reach market salvag use time
darzalex entrench line durat drug year month henc
competit impact probabl minim
ration ramp-up spend profit manag set
hike advanc genmab proprietari pipelin ascrib modest
npv tisotumab vedotin preclinical/phas asset repres upsid
pt base sum-of-the-part valuat larg compris probability-
adjust npv darzalex plu contribut arzerra humax-tf janssen
duobodi collabor togeth net risk includ clinic trial failur
success commercialis darzalex failur execut futur out-licens deal
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
see upsid darzalex multipl myeloma
like becom standard care across line
therapi ww peak sale least
anticip multipl pipelin catalyst potenti
drive stock plu broad early-stag pipelin
price dkk per share base npv larg
darzalex mm plu arzerra royalti tisotumab vedotin
janssen duobodi collabor net
encourag efficaci darzalex phase ii trial studi
indic beyond mm could add least dkk
posit arzerra phase result line nhl could add
posit pivot phase ii cervic cancer data tisotumab
vedotin could add least dkk
encourag earli phase ii result humax-axl
solid tumour could add dkk
potenti catalyst could boost npv deriv price
around dkk
regulatori delay line mm safeti concern and/or
greater competit threat darzalex could reduc npv
least dkk
poor efficaci darzalex non-mm indic cut npv
 dkk
insuffici efficaci safeti concern tisotumab
vedotin could lower npv dkk
neg arzerra clinic data line nhl could lower
royalti reduc npv around dkk
near-term setback could reduc npv
deriv price around dkk
forecast sustain profit even spend
early-stag intern programm ramps-up
darzalex catapult earn trajectori
around dkk net septemb
suffici maximis valu
pipelin technolog platform view futur
out-licens deal preclin asset potenti
arzerra phase line nhl data
increment tisotumab vedotin phase i/ii result
addit first data humax-axl
data darzalex combin drug treat
solid tumour
addit duobodi hexabodi technolog platform
deal updat
page
pleas see import disclosur inform page report
reiter buy pt dkk
remain confid continu impress sale trajectori darzalex
daratumumab multipl myeloma mm partner janssen part
buy on-going expans clinic programm justifi belief
darzalex could becom backbon therapi mm potenti role
treat blood cancer possibl solid tumour combin
support continu share price momentum investor percept
valu genmab broad early-stag pipelin notabl tissu factor
antibody-drug conjug tisotumab vedotin pivot phase ii
upsid possibl increment technolog platform strateg partnership
forecast sustain profit even spend early-stag
intern programm ramp darzalex potenti catapult
earn trajectori dkk per share price mainli
underpin npv darzalex mm also ascrib valu arzerra
royalti lymphoma sale tisotumab vedotin janssen duobodi
collabor plu net futur out-licens deal
hike darzalex mm sale ww peak
longer averag durat therapi updat result phase
pollux trial american societi hematolog confer
decemb darzalex line mm rd report month median
durat treatment vs month rd updat data phase
castor studi darzalex line mm vd report month median
durat treatment continu single-ag mainten base
averag two studi increas averag durat
darzalex use line mm month month
us ex-u
suggest like prolong use line treatment given hike
durat therapi line mm increas length time
assum line newly-diagnos patient receiv darzalex around three year
month
higher peak penetr smm clinician feedback overwhelmingli
risk-reward use darzalex accept intermediate-high risk
smolder multipl myeloma smm patient given likelihood
progress symptomat mm current guidelin recommend monitor
patient everi month forecast peak us penetr
smm prior conserv estim support posit
phase ii centauru data on-going phase aquila trial
long-term declin use salvag therapi given potenti
emerg competit threat bcma and/or antibody-drug
conjug addit possibl therapi assum adopt
darzalex salvag line treatment peak around
respect penetr declin half maximum level longer-
term believ also account patient receiv darzalex earlier line
therapi becom inelig refractori albeit scant evid
present suggest malign plasma cell develop long-term resist
therapi
page
pleas see import disclosur inform page report
signific presenc underpin confid
plethora darzalex present confirm drug alreadi regard
backbon mm encourag earli amyloidosi smolder mm data
plu first look pre-mix subcutan formul dose within
minut phase bcma target therapi perhap stole
show mm darzalex becom entrench use line struggl
impress earli amyloidosi data investig sponsor phase ii
darzalex monotherapi relaps al light chain amyloidosi present
show high haematolog respons rate rapid effect first
infus plu cardiac renal respons infus relat reaction
manag like less common/sever myeloma clinician felt
studi clearli warrant note phase andromeda trial
recent initi newli diagnos al amyloidosi cybord
darzalex
monotherapi intermediate-high risk smolder mm robust expect
given recent initi phase aquila trial smm current standard-
of-car long-term mainten dose provid greatest benefit
overal respons rate orr includ complet respons cr fail
meet predefin co-primari endpoint
cohort clearli met co-primari hurdl median month
support develop
darzalex dose conveni focu updat phase ib pavo
trial show pre-mix co-formul darzalex dose
manual without pump subcutan minut encouragingli
patient infus reaction dose one grade
addit hard compar cross-trial higher drug concentr
pre-mix form may yield better respons intraven dose
asid note two on-going trial utilis split dose design
mitig capac constraint site given current administr
well avoid potenti toler issu concomit intraven
dose carfilzomib kyproli interestingli independ us centr report
acceler dose infus minut typic
detail phase line alycon data relev eu abstract
outlin last month darzalex vmp significantli reduc risk progress
half vs vmp alon median nr vs month impress
cr/scr vs higher mrd neg vs like
import predict marker surviv new safeti signal
note vmp standard-of-car ex-u region albeit less commonli
use us rd-base regimen domin
bcma stole show
car-t bcma phase i/ii data salvag rrmm patient median prior line
impress orr includ cr durat respons
least mo notabl cr patient mrd neg buy
partner celgen celg buy initi karmma pivot phase ii trial
result potenti high interest move earlier line
therapi phase studi line rrmm vs darzalex-pom-d start
myeloma kol jefferi host dinner excit bcma
target strategi particularli assum karmma pivot trial confirm
data infrastructure/logist administ car-t therapi develop envisag
gain meaning share mm salvag therapi howev time
darzalex like entrench backbon line treatment durat
therapi year month henc competit impact probabl minim
page
pleas see import disclosur inform page report
clearli see signific potenti car-t target bcma view given
collabor chines compani nanj legend decemb agre
pay up-front plu undisclos futur mileston profit share gain
ww right bcma car-t data present car-t
report evalu chines patient orr stringent cr
albeit median three prior line therapi plan initi studi us
europ estim least one year behind bluebird
bcma show robust durabl respons orr ocular
toxic remain potenti concern toxin albeit manag dose
modif note bispecif part janssen/genmab
duobodi collabor current phase rrmm
darzalex drive paradigm shift mm treatment
impress phase ii siriu monotherapi data darzalex salvag
treatment mm justifi fda expedit regulatori review approv
breakthrough therapi novemb eu approv receiv may
posit result phase castor pollux combin
studi demonstr unpreced benefit relapsed-
refractori mm lead us approv top current standard-of-car
novemb european approv april phase
alcyon line studi vmp stop efficaci interim analysi
august lead us eu file physician check suggest
enthusiasm widespread adopt across treatment paradigm like
becom new backbon therapi underscor confid
substanti commerci potenti timelin advantag versu compet
sale forecast mm plu indic includ
amyloidosi myelodysplast syndrom solid tumour genmab
elig receiv tier royalti ww sale partner janssen
valuat dkk per share probabl success mm plu
risk-adjust indic contribut dkk per share
news flow us eu approv line mm vmp around mid-
potenti interim analysi phase maia rd trial line mm
initi phase i/ii data solid tumour combin drug
subcutan formul could game-chang
accord expert subcutan administ darzalex could game-chang
particularli earlier line therapi long-term mainten potenti treatment
asymptomat smolder mm pre-mix co-formul darzalex
dose manual without pump subcutan
minut clinician eagerli await subcut form overcom perceiv limit
darzalex name long infus time hr first hr long term infusion-
relat reaction conveni formul also strengthen competit
posit rel therapi develop view notabl
boast shorter infus time also isatuximab phase
pomalyst intriguingli also heard clinician idea re-intensifi
darzalex dose relaps possibl made viabl subcut formul
data on-going plan studi could expand potenti
multipl phase mm studi darzalex current conduct plan
includ maia rd line mm patient inelig stem cell transplant
sct cassiopeia vtd line mm patient elig sct apollo
pom-d pomalidomid dexamethason rrmm patient
previous treat immunomodulatori drug proteasom
inhibitor pi candor kd rrmm patient primari endpoint
page
pleas see import disclosur inform page report
trial except cassiopeia also initi primari analysi use
stringent complet respons scr earlier evalu darzalex benefit
patient elig transplant anticip result
expect interim analysi maia around
also explor potenti darzalex non-mm indic possibl expand
potenti still darzalex clinic trial monotherapi combin
checkpoint inhibitor mm nktcl myelodysplast syndrom md
amyloidosi submit ind us fda initi clinic trial
rheumatoid arthriti understand could first sever potenti
autoimmun indic pursu basi promis preclin data
use solid tumour could catapult darzalex anoth leagu
preclin proof-of-concept data use darzalex solid tumour
disclos janssen view initi clinic trial indic
extrem encourag suggest data to-dat support result
first trial solid tumour expect earliest henc
time includ sale npv contribut indic forecast
number trial solid tumour announc studi anticip
initi due cours
addit daratumumab combin treatment nivolumab opdivo
checkpoint inhibitor checkmat trial metastat colon
cancer checkmat trial virus-associ tumour phase i/ii
studi advanc metastat solid tumour studi
sponsor bristol-my squibb hold
daratumumab combin atezolizumab tecentriq checkpoint
patient previous treat
advanc metastat non-smal cell lung cancer sponsor janssen
collabor genentech part roch vx chf buy
note research univers texa md anderson cancer centr
identifi novel immun checkpoint protein abstract present
asco-sitc clinic immuno-oncolog symposium februari shown
upregul tumour cell also regulatori cell
myeloid-deriv suppressor cell mdsc tumour microenviron
inhibit activ cytotox cell conclud blockad
may use mean overcom resist therapi treatment
independ preclin studi provid rational use darzalex
combin immun checkpoint inhibitor haematolog cancer also
page
pleas see import disclosur inform page report
